Ami clinical trials

Explore recruiting ami clinical trials.

Recruiting ami studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Ami trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

IOCYTE AMI-3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intravenous FDY-5301 in Patients with an Anterior ST-Elevation Myocardial Infarction

Portugal, Czechia, Spain, Slovakia, Hungary, Netherlands +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Effects of ziltivekimab versus placebo on coronary atherosclerosis in patients with acute myocardial infarction. A serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study

Italy, Netherlands, Austria, Denmark, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction

Austria, Netherlands, Denmark, Poland, Romania, Slovakia +17 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

ARTEMIS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction.

Greece, Bulgaria, Germany, Poland, Netherlands, Italy +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in a Genentech-and/Or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study

France, Austria, Spain, Hungary, Poland, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA)

Spain

Phase III and phase IV (Integrated) EU CTIS Study details

Ami trials by city

Ami in Toronto Ami in Vancouver Ami in Montreal Ami in Calgary Ami in Edmonton Ami in Ottawa Ami in Winnipeg Ami in Quebec City Ami in Hamilton Ami in Kitchener Ami in London Ami in Halifax Ami in New York Ami in Los Angeles Ami in Chicago Ami in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease